Who are GnRH agonist/antagonist's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lupron, Micronor, Ganirelix Acetate, Cetrolix Acetate, Half-Dose Depot Triptorelin, Degarelix (LHRH antagonist), Leuprolide acetate in depot suspension.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gnrh-agonist-antagonist.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

GnRH agonist/antagonist — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GnRH agonist/antagonist (GnRH agonist/antagonist) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH agonist/antagonist. Area: Oncology.

marketed GnRH agonist/antagonist GnRH receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

GnRH agonist/antagonist (GnRH agonist/antagonist) — Memorial Sloan Kettering Cancer Center. GnRH agonists/antagonists suppress gonadotropin-releasing hormone signaling to reduce sex hormone production, used in oncology to manage hormone-sensitive cancers and their treatment side effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GnRH agonist/antagonist TARGET	GnRH agonist/antagonist	Memorial Sloan Kettering Cancer Center	marketed	GnRH agonist/antagonist	GnRH receptor
Lupron	leuprorelin	Accord Healthcare S.L.U.	marketed	Gonadotropin Releasing Hormone Receptor Agonist	GnRH receptors	1985-01-01
Micronor	norethisterone	Johnson & Johnson	marketed	Progestin	GnRH receptors	1962-01-01
Ganirelix Acetate, Cetrolix Acetate	Ganirelix Acetate, Cetrolix Acetate	Assaf-Harofeh Medical Center	marketed	GnRH antagonist	GnRH receptor
Half-Dose Depot Triptorelin	Half-Dose Depot Triptorelin	Tehran University of Medical Sciences	marketed	GnRH agonist	GnRH receptor
Degarelix (LHRH antagonist)	Degarelix (LHRH antagonist)	Rabin Medical Center	marketed	GnRH antagonist	GnRH receptor
Leuprolide acetate in depot suspension	Leuprolide acetate in depot suspension	Colorado Center for Reproductive Medicine	marketed	GnRH agonist	GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-22 — Lupron · 9617303 · US
2031-02-05 — Lupron · 8921326 · US

Sponsor landscape (GnRH agonist/antagonist class)

Memorial Sloan Kettering Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GnRH agonist/antagonist — Competitive Intelligence Brief. https://druglandscape.com/ci/gnrh-agonist-antagonist. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab